Strategy Asset Managers LLC Makes New $221,000 Investment in The Clorox Company (NYSE:CLX)

Strategy Asset Managers LLC acquired a new position in The Clorox Company (NYSE:CLXGet Rating) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,587 shares of the company’s stock, valued at approximately $221,000.

Several other institutional investors have also recently modified their holdings of CLX. Dark Forest Capital Management LP acquired a new position in shares of Clorox in the third quarter worth about $25,000. Newbridge Financial Services Group Inc. increased its stake in shares of Clorox by 185.2% during the fourth quarter. Newbridge Financial Services Group Inc. now owns 154 shares of the company’s stock worth $27,000 after purchasing an additional 100 shares in the last quarter. TAP Consulting LLC purchased a new stake in shares of Clorox during the fourth quarter worth about $27,000. FSB Premier Wealth Management Inc. purchased a new stake in shares of Clorox during the fourth quarter worth about $28,000. Finally, Financial Avengers Inc. increased its stake in shares of Clorox by 119.7% during the fourth quarter. Financial Avengers Inc. now owns 167 shares of the company’s stock worth $29,000 after purchasing an additional 91 shares in the last quarter. Institutional investors and hedge funds own 77.28% of the company’s stock.

Clorox stock opened at $132.14 on Thursday. The firm has a market cap of $16.26 billion, a PE ratio of 35.81, a price-to-earnings-growth ratio of 4.21 and a beta of 0.18. The Clorox Company has a 52-week low of $120.50 and a 52-week high of $191.75. The company has a quick ratio of 0.40, a current ratio of 0.71 and a debt-to-equity ratio of 3.28. The company’s 50 day moving average is $142.61 and its two-hundred day moving average is $151.67.

Clorox (NYSE:CLXGet Rating) last announced its quarterly earnings data on Monday, May 2nd. The company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $0.97 by $0.34. Clorox had a net margin of 6.44% and a return on equity of 92.98%. The company had revenue of $1.81 billion for the quarter, compared to the consensus estimate of $1.81 billion. During the same period in the prior year, the firm posted $1.62 EPS. On average, equities research analysts anticipate that The Clorox Company will post 4.16 earnings per share for the current fiscal year.

A number of research firms have recently commented on CLX. Barclays cut their target price on shares of Clorox from $126.00 to $115.00 and set an “underweight” rating for the company in a research note on Monday, May 23rd. Wells Fargo & Company dropped their price objective on shares of Clorox from $130.00 to $120.00 and set an “underweight” rating for the company in a research note on Tuesday. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Clorox from $145.00 to $132.00 in a research note on Tuesday. DA Davidson dropped their price objective on shares of Clorox from $127.00 to $123.00 in a research note on Tuesday, May 3rd. Finally, StockNews.com started coverage on shares of Clorox in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Nine analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, Clorox has an average rating of “Reduce” and a consensus price target of $140.69.

In other Clorox news, COO Eric H. Reynolds sold 585 shares of the stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $154.83, for a total value of $90,575.55. Following the sale, the chief operating officer now directly owns 17,289 shares of the company’s stock, valued at approximately $2,676,855.87. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director A D. David Mackay sold 1,000 shares of the stock in a transaction that occurred on Thursday, June 2nd. The shares were sold at an average price of $140.63, for a total transaction of $140,630.00. Following the completion of the sale, the director now directly owns 600 shares in the company, valued at $84,378. The disclosure for this sale can be found here. Corporate insiders own 0.58% of the company’s stock.

About Clorox (Get Rating)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brand names; professional cleaning and disinfecting products under the CloroxPro, Clorox Healthcare, and Clorox Total 360 brand names; professional food service products under the Hidden Valley brand name; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brand names in the United States.

Recommended Stories

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Want More Great Investing Ideas?

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.